Space Station Spotlight Newsletter
Welcome to Space Station Spotlight, a monthly newsletter from the ISS National Laboratory. Here’s where you can find all the latest R&D happenings on the space station, see what our partners are up to, and learn how you can elevate your research to new heights by leveraging the unique space environment.

What's new at the ISS National Lab?

NASA astronaut Frank Rubio poses in the cupola before returning to Earth.

NASA astronaut Frank Rubio returned from space after a record-setting 371-day mission.

Rubio launched to space in 2022 and spent more than a year conducting science investigations, many sponsored by the ISS National Lab. Read more here.

From left: Roscosmos cosmonaut Andrey Fedyaev, NASA astronaut Warren Woody Hoburg, NASA astronaut Stephen Bowen, and UAE astronaut Sultan Alneyadi, are seen inside the SpaceX Dragon Endeavour spacecraft shortly after landing in the Atlantic Ocean off the Florida coast.

Rubio wasn’t the only astronaut who returned to Earth—SpaceX’s Dragon spacecraft “Endeavour” brought the Crew-6 astronauts home in early September, following a six-month science expedition.

NASA astronauts Stephen Bowen and Warren “Woody” Hoburg, along with United Arab Emirates astronaut Sultan Alneyadi and Roscosmos cosmonaut Andrey Fedyaev, spent six months in space conducting critical research for scientists on the ground.
Redwire unboxes its first human meniscus print after returning to Earth with NASAs Crew 6 astronauts.

The space station crew carried out in-orbit activities for multiple ISS National Lab-sponsored investigations this past month.

One of those investigations focused on 3D printing a human meniscus (the protective piece of cartilage between the bones in the knee). This was the first successful print of a complete human tissue, and the sample was returned to Earth for analysis.

Igniting Innovation: Science in Space to Cure Disease on Earth

A new White House fact sheet of actions to accelerate progress on the Administration’s Cancer Moonshot initiative highlighted the ISS National Lab and NASA as key players in advancing cancer research.

Through the recently released solicitation Igniting Innovation: Science in Space to Cure Disease on Earth, the ISS National Lab is partnering with NASA’s Biological and Physical Sciences Division to fund cancer research and technology development leveraging the unique conditions of space.

Partner News

Bishop Airlock hosted its first external payload. Designed and built by Nanoracks, a Voyager Space Company, Bishop Airlock hosted Gambit, an external payload designed to test the capabilities of the external platform, which could lead to increased utilization on the ISS.

Axiom Space announced the crew of its third private astronaut mission. Axiom Space is slated to fly its third private astronaut mission to the ISS in January 2024 and recently announced the members of the crew. Read about the multinational crew, led by Michael López-Alegría, here.

Aegis Aerospace launched its 10th MISSE payload to the ISS. Aegis Aerospace successfully launched its 10th MISSE mission, MISSE-18, to the space station. MISSE-18 includes 13 unique experiments. Learn more here.

Space Tango named S. Sita Sonty new CEO. Sonty will succeed Twyman Clements as company CEO, and Clements will take on a new role as company president. Learn more about Sonty, who was previously the head of human spaceflight at SpaceX, here.

LEO Market Update

In a new investment perspective article, ISS National Lab Director of Investment and Economic Analysis Sven Eenmaa provides a capital markets snapshot.
For further insight on fundamental investment perspectives from the space sector, including funding criteria in infrastructure, in-space applications, and services in low Earth orbit, watch the recording of the ISS Research and Development Conference (ISSRDC ) investor panel session.

moon over clouds

Funding Opportunities

iss052e018944 (7 24 2017) NASA astronaut Peggy Whitson working with the Efficacy and Metabolism of Azonafide Antibody Drug Conjugates in Microgravity (ADCs in Microgravity). The ADCs in Microgravity investigation evaluates new antibody drug conjugates that combine an immune activating drug with antibodies in order to target only cancer cells, increasing the effectiveness of chemotherapy and reducing its side effects. In microgravity, cancer cells grow in three dimensional, spheroid structures that closely resemble their form in the human body, allowing for better drug testing. This investigation may accelerate development of targeted therapies for cancer patients.
An ISS National Lab solicitation to advance research on cancer and other diseases attracted record-breaking interest. The concept submission period for the Igniting Innovation research announcement closed on September closed on September 26, and had an overwhelming response. The solicitation, in partnership with NASA’s Biological and Physical Sciences Division, is offering up to $5 million in total funding for multiple translational and transformative research and technology development projects. Learn more here.


The latest issue of Upward, official magazine of the ISS National Lab, delves into exciting results from space-based R&D. Download the issue here.

Read the Upward feature “Heating Things Up in Microgravity” to see how scientists are leveraging the orbiting laboratory for research that could lead to new ways to improve fire safety on Earth.

Learn how BioServe Space Technologies supported a pioneering experiment that laid the foundation for future space-based cardiovascular stem cell research. BioServe Director Stefanie Countryman and researcher Arun Sharma discussed this groundbreaking investigation—which is featured in the most recent issue of Upward—in a fireside chat at this year’s ISS Research and Development Conference.

ESA astronaut Alexander Gerst and NASA astronaut Reid Wiseman work in the Microgravity Science Glovebox onboard the ISS

Subscribe to our monthly newsletter.

Subscribe to Space Station Spotlight Newsletter
Subscribe to ISS National Lab
Do not Subscribe
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Share with a friend: